265 related articles for article (PubMed ID: 34058731)
21. Evaluation of the efficacy of sacral neuromodulation in the treatment of voiding dysfunction after endometriosis surgery.
Aublé A; Gazdovich S; Dégremont S; Pfister C; Roman H; Bridoux V; Leroi AM; Cornu JN
Prog Urol; 2023 Dec; 33(17):1073-1082. PubMed ID: 37951811
[TBL] [Abstract][Full Text] [Related]
22. Does sacral neuromodulation lead to relevant reduction in the need for intermittent catheterization? A single-center experience on patients with chronic urinary retention.
Denzinger S; Nowrotek A; Weingart P; Burger M; Wieland WF; Rößler W; Otto W
Neuromodulation; 2012; 15(6):586-91; discussion 591. PubMed ID: 22672285
[TBL] [Abstract][Full Text] [Related]
23. Sacral Neuromodulation: Device Improvement and Current Applications in Urology.
Spilotros M; Gerbasi S; Lasorsa F; de Rienzo G; Balducci L; Ditonno P; Lucarelli G
Medicina (Kaunas); 2024 Mar; 60(3):. PubMed ID: 38541235
[TBL] [Abstract][Full Text] [Related]
24. Patients with Sacral Neuromodulation: What Are the Factors Affecting Their Therapy Satisfaction?
Banakhar M; Hassouna M
Urol Int; 2019; 103(4):450-453. PubMed ID: 31574517
[TBL] [Abstract][Full Text] [Related]
25. International Continence Society best practice statement for use of sacral neuromodulation.
Goldman HB; Lloyd JC; Noblett KL; Carey MP; Castaño Botero JC; Gajewski JB; Lehur PA; Hassouna MM; Matzel KE; Paquette IM; de Wachter S; Ehlert MJ; Chartier-Kastler E; Siegel SW
Neurourol Urodyn; 2018 Jun; 37(5):1823-1848. PubMed ID: 29641846
[TBL] [Abstract][Full Text] [Related]
26. Sacral neuromodulation treatment for urinary voiding dysfunctions: results of treatment with the largest single-center series in a tertiary referral center in Turkey.
Kütükoğlu MU; Altuntaş T; Şahin B; Onur AR
Turk J Med Sci; 2023 Feb; 53(1):206-210. PubMed ID: 36945940
[TBL] [Abstract][Full Text] [Related]
27. The effect of sacral neuromodulation on pudendal nerve function and female sexual function.
Parnell BA; Howard JF; Geller EJ
Neurourol Urodyn; 2015 Jun; 34(5):456-60. PubMed ID: 24615871
[TBL] [Abstract][Full Text] [Related]
28. Medium-term outcomes of sacral neuromodulation in patients with refractory overactive bladder: A retrospective single-institution study.
Kaaki B; Gupta D
PLoS One; 2020; 15(7):e0235961. PubMed ID: 32645082
[TBL] [Abstract][Full Text] [Related]
29. PNE versus 1st stage tined lead procedure: a direct comparison to select the most sensitive test method to identify patients suitable for sacral neuromodulation therapy.
Leong RK; De Wachter SG; Nieman FH; de Bie RA; van Kerrebroeck PE
Neurourol Urodyn; 2011 Sep; 30(7):1249-52. PubMed ID: 21404317
[TBL] [Abstract][Full Text] [Related]
30. Sacral neuromodulation outcomes in male patients with chronic urinary retention.
Saber-Khalaf M; Abtahi B; Gonzales G; Helal M; Elneil S
Neuromodulation; 2015 Jun; 18(4):329-34; discussion 334. PubMed ID: 25655708
[TBL] [Abstract][Full Text] [Related]
31. Sacral neuromodulation for lower urinary tract dysfunction.
Van Kerrebroeck PE; Marcelissen TA
World J Urol; 2012 Aug; 30(4):445-50. PubMed ID: 21989816
[TBL] [Abstract][Full Text] [Related]
32. Prolonged percutaneous SNM testing does not cause infection-related explanation.
Amend B; Bedke J; Khalil M; Stenzl A; Sievert KD
BJU Int; 2013 Mar; 111(3):485-91. PubMed ID: 22738331
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and acceptance of the sacral neuromodulation in the treatment of female lower urinary tract dysfunctions.
Adile B; Speciale P; Gugliotta G; Consiglio P; Manzone M; Adile G; Saitta S; Perino A; Calagna G
Minerva Ginecol; 2018 Apr; 70(2):236-238. PubMed ID: 29083137
[No Abstract] [Full Text] [Related]
34. Long-term results of sacral neuromodulation with the tined lead procedure.
Marcelissen TA; Leong RK; de Bie RA; van Kerrebroeck PE; de Wachter SG
J Urol; 2010 Nov; 184(5):1997-2000. PubMed ID: 20850820
[TBL] [Abstract][Full Text] [Related]
35. Sacral neuromodulation using the standardized tined lead implantation technique with a curved vs a straight stylet: 2-year clinical outcomes and sensory responses to lead stimulation.
Vaganée D; Kessler TM; Van de Borne S; De Win G; De Wachter S
BJU Int; 2019 May; 123(5A):E7-E13. PubMed ID: 30537223
[TBL] [Abstract][Full Text] [Related]
36. The Value of Ambulatory Urodynamics in the Evaluation of Treatment Effect of Sacral Neuromodulation.
Drossaerts J; Rademakers KLJ; Rahnama'i SM; Marcelissen T; Van Kerrebroeck P; van Koeveringe G
Urol Int; 2019; 102(3):299-305. PubMed ID: 30612126
[TBL] [Abstract][Full Text] [Related]
37. Improving clinical outcomes for women with overactive bladder or urinary retention symptoms: a comparison of motor response voltages (1-9 V) during Stage 1 sacral neuromodulation.
Marinkovic SP; Ford JC
BJU Int; 2018 Sep; 122(3):472-479. PubMed ID: 29637712
[TBL] [Abstract][Full Text] [Related]
38. Sacral neuromodulation for urinary retention.
Kessler TM; Fowler CJ
Nat Clin Pract Urol; 2008 Dec; 5(12):657-66. PubMed ID: 19002127
[TBL] [Abstract][Full Text] [Related]
39. Is sacral neuromodulation effective in patients with Parkinson's disease? A retrospective review.
Martin S; Zillioux J; Goldman HB
Neurourol Urodyn; 2022 Apr; 41(4):955-961. PubMed ID: 35238421
[TBL] [Abstract][Full Text] [Related]
40. Sacral neuromodulation for lower urinary tract dysfunction and impact on erectile function.
Lombardi G; Mondaini N; Giubilei G; Macchiarella A; Lecconi F; Del Popolo G
J Sex Med; 2008 Sep; 5(9):2135-40. PubMed ID: 18637993
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
